The Monthly Weight-Loss Shot That Just Raised $73M

The company also has a semaglutide biosimilar (ZT001) that it's commercializing through partnerships with Tonghua Dongbao Pharmaceutical for diabetes and Imeik for weight management. In total, QL Biopharm says it has 10 recombinant protein drugs in development, including two international "class I" innovators (the regulatory designation for truly novel drugs).

Why OrbiMed and Qiming Are Betting Big

Let's talk about the money people, because the investor list tells a story of its own.

OrbiMed doesn't sprinkle cash around casually. The firm raised $1.86 billion for its Fund V in August 2025 and has been strategically deploying capital into China-origin biotechs with late-stage clinical assets. In 2025 alone, OrbiMed led a $131 million pre-IPO round for Minghui Pharmaceutical (a bispecific antibody company) and backed Epigenic Therapeutics in a $60 million Series B. The pattern is clear: OrbiMed is looking for companies approaching inflection points, and a Phase III GLP-1 asset fits that thesis perfectly.

Qiming Venture Partners brings its own credibility. The firm has invested in nearly 30 AI-plus-medical innovation companies and backed winners like Insilico Medicine (which became Hong Kong's largest biotech IPO in 2025). Qiming has been deliberately steering its healthcare portfolio toward biotech over more politically sensitive sectors, a smart hedge given ongoing U.S.-China tensions.

When both of these firms show up in the same cap table, it sends a signal: this isn't speculative seed money. This is "we think you're heading toward commercialization" money.

The Bigger Picture: China's GLP-1 Gold Rush

QL Biopharm isn't the only Chinese company chasing GLP-1 riches. Corxel recently raised $287 million in a Series D1 for its own oral GLP-1 program. The metabolic disease space in China is attracting capital like a magnet, and for good reason: China has one of the world's largest diabetic and obese populations, and domestic demand for effective treatments is enormous.

What makes QL Biopharm's position interesting is the combination of novelty and near-term commercial potential. The company has a GMP manufacturing facility certified by Turkey's regulatory authority (TITCK) as of September 2025, which means it's not just running clinical trials; it's building the infrastructure to actually make and sell drugs. That's the difference between a science project and a business.

The founding team adds another layer of credibility. CEO Dr. Zhang Xujia built the company with a core team that cut its teeth at Novo Nordisk's R&D center, the very company behind Ozempic and Wegovy. They know the GLP-1 playbook inside and out. They're just trying to write the next chapter.

What to Watch

The HORIZON-1 Phase III trial is the main event. Everything hinges on whether zovaglutide can prove that once-monthly dosing delivers comparable (or better) weight loss results without sacrificing safety. Phase III trials are expensive, grueling, and full of surprises; plenty of promising drugs have stumbled at this stage.

But $72.9 million buys a lot of runway. And with OrbiMed and Qiming in the corner, QL Biopharm has the kind of backers who can help navigate regulatory submissions, future fundraising, and potential partnerships.

The GLP-1 market is getting crowded. Weekly injections are already old news. Daily pills are on the way. In that context, a monthly shot isn't just a nice-to-have; it's potentially a category-defining product. If QL Biopharm can deliver the data, the line of suitors (and acquirers) will be long.

For now, the company has the cash, the team, and the clinical momentum. The only question left is the one that always matters most in biotech: does the drug actually work?